欢迎使用辉瑞医谷移动端
马上下载      

Management of BPH – AUA

2019年1月24日 良性前列腺增生

2004, EAU

Subject: Benign prostatic hyperplasia (BPH) is a histologic diagnosis that refers to the proliferation of smooth muscle and epithelial cells within the prostatic transition zone. The prevalence and the severity of lower urinary tract symptoms (LUTS) in the aging male can be progressive and is an important diagnosis in the healthcare of patients and the welfare of society. In the management of bothersome LUTS, it is important that healthcare providers recognize the complex dynamics of the bladder, bladder neck, prostate, and urethra, in addition to the fact that symptoms may result from interactions of these organs as well as with the central nervous system or other systemic diseases (e.g., metabolic syndrome, congestive heart failure). Despite the more prevalent (and often first line) use of medical therapy for men suffering from LUTS attributed to BPH, there still remain clinical scenarios where surgery is indicated as the initial intervention for LUTS/BPH and should be recommended, providing other medical comorbidities do not preclude this approach. It is the hope that this revised guideline will provide a useful reference on the effective evidence-based surgical management of male LUTS secondary to BPH (LUTS/BPH). Please see the accompanying algorithm for a summary of the surgical procedures detailed in the guideline.

Sources

请注意: 点击资源链接后,您即将离开辉瑞医学信息网站。     

 

本网站仅医疗卫生专业人士使用 | 辉瑞中国医学信息部 产品咨询热线 400-910-0055
©2019 Pfizer | 有关声明 | 隐私政策 | 客户服务 | 友情链接 | 辽ICP备14012080号-1 | 证书编号:(辽)-非经营性-2018-0005